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Abstract
Toll-like receptor 2-agonistic lipopeptides typified by S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-R-
cysteinyl-S-serine (PAM2CS) compounds are potential vaccine adjuvants. We had previously
determined that at least one acyl group of optimal length (C16) and an appropriately orientated
ester carbonyl group is essential for TLR2-agonistic activity. We now show that these structurally
simpler analogues display agonistic activities with human, but not murine TLR2. SAR studies on
the monoacyl derivatives show that the optimal acyl chain length is C16, and aryl substituents are
not tolerated. A variety of alkyl and acyl substituents on the cysteine amine were examined. All N-
alkyl derivatives were inactive. In contradistinction, short-chain N-acyl analogues were found to
be highly active, with a clear dependence on the chain length. A cysteine N-acetyl analogue was
found to be the most potent (EC50: 1 nM), followed by the N-butyryl analogue. The N-acetyl
analogue is human TLR2-specific, with its potency comparable to that of PAM2CS.
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Introduction
Vaccines are perhaps one of the most successful medical interventions against infectious
disease.1 An important component in the design of effective vaccines is the incorporation of
appropriate immune potentiators (also termed adjuvants), along with the antigen; adjuvants
initiate early innate immune responses which lead to the induction of robust and long-lasting
adaptive immune responses.2 More than eight decades have elapsed since the discovery of
adjuvanticity of aluminum salts (primarily phosphate and hydroxide) by Glenny and
coworkers,3 and the repertoire of investigational adjuvants has grown to encompass a very
wide range of materials;4 however, aluminum salt-based mineral salts (generically, and
incorrectly, termed “alum”) have, until the recent introduction of 3-O-desacyl-4'-
monophosphoryl lipid A (MPL),5 remained the only adjuvants currently approved by the
FDA. Aluminum salts have enjoyed a good safety record, but are weak adjuvants for
antibody induction, promoting a TH2-skewed, rather than a TH1 response.6,7 Furthermore,
not only are aluminum salts ineffective at inducing cytotoxic T lymphocyte (CTL) or
mucosal IgA antibody responses, but also have an undesirable propensity to induce IgE
isotype switching, which has been associated with allergic reactions in some subjects.6,7
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Toll-like receptors (TLRs) are pattern recognition receptors present on diverse cell types.
TLRs recognize specific molecular patterns present in molecules that are broadly shared by
pathogens but are sufficiently different so as to be distinguishable from host molecules, and
are collectively referred to as pathogen-associated molecular patterns (PAMPs).8,9 There are
10 TLRs in the human genome; these are trans-membrane proteins with an extracellular
domain having leucine-rich repeats (LRR) and a cytosolic domain called the Toll/IL-1
receptor (TIR) domain.9
The ligands for these receptors are highly conserved microbial molecules such as
lipopolysaccharides (LPS) (recognized by TLR4), lipopeptides (TLR2 in combination with
TLR1 or TLR6), flagellin (TLR5), single stranded RNA (TLR7 and TLR8), double stranded
RNA (TLR3), CpG motif-containing DNA (recognized by TLR9), and profilin present on
uropathogenic bacteria (TLR 11).10,11 TLR1, −2, −4, −5, and −6 respond to extracellular
stimuli, while TLR3, −7, −8 and −9 respond to intracytoplasmic PAMPs, being associated
with the endolysosomal compartment.9 The activation of TLRs by their cognate ligands
leads to production of inflammatory cytokines, and up-regulation of MHC molecules and
co-stimulatory signals in antigen-presenting cells as well as activating natural killer (NK)
cells (innate immune response), in addition to priming and amplifying T-, and B-cell
effector functions (adaptive immune responses).12–15 Thus, TLR stimuli serve to link innate
and adaptive immunity13 and can therefore be exploited as powerful adjuvants in eliciting
both primary and anamnestic immune responses.
We have recently begun to explore in detail, structure-activity relationships (SAR) of several
immunostimulatory chemotypes.16–24 Our attention has focused particularly on agonists of
TLR2, exemplified by the S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-R-cysteinyl-S-serine
(PAM2CS) chemotype,17,23 which distinguishes itself from virtually all other TLR agonists
in that although the lipopeptide is devoid of any detectable pro-inflammatory activity in ex
vivo human blood models (as defined by the production of detectable levels of TNF-α,
IL-1β, IL-6, or IL-8),25 or of local reactogenicity and pyrogenicity in rabbit models,18 it is
potently adjuvantic in murine models of immunization,25 suggesting that this chemotype
may be a safe and effective adjuvant. Extensive SAR on the PAM2CS class of compounds23
led to simplified second-generation mono-acyl lipopeptides in which the spacing between
the ester-linked acyl group and the thioether was found to play a crucial role in determining
activity; homologation of the ethylene-bridged compound (6d in Scheme 1) by one
methylene unit resulted in complete abrogation of activity.17
The structurally simpler, synthetically more accessible, and water-soluble 6d with its potent
TLR2- agonistic properties in both primary screens employing human TLR2, as well as
secondary screens in ex vivo human blood models presented an excellent lead. Prior to
commencing immunization studies in rodent and non-rodent models, this compound was
subjected to further evaluation. We found, entirely to our surprise, that unlike PAM2CS, 6d
showed exquisite specificity in activating human TLR2 (hTLR2), but not murine TLR2
(mTLR2), suggesting that the binding mode of 6d to TLR2 may be substantially different
from that of PAM2CS. This conjecture was strengthened by the observation that N-acylation
of 6d with a palmitoyl group resulted in complete loss of hTLR2-agonistic activity, which is
unexpected given the pronounced activity of the analogous, N-palmitoylated PAM2CS
compound (PAM3CS), and crystallographic evidence for the engagement of the TLR2/TLR1
heterodimer by PAM3CS.26,27 These preliminary findings warranted a detailed SAR on the
monoacylated lipopeptide chemotype, our goals being not only to identify potentially more
potent analogues of 6d, but also to attempt to understand the structural correlates
determining human versus murine TLR2 specificity.
Salunke et al. Page 2














The SAR of the mono-acyl derivatives began with a careful exploration of the nature of the
ester-linked acyl group on the mercaptoethanol fragment of the lipopeptide; specifically, we
wished to determine the optimal chain length corresponding to maximal TLR2-stimulatory
activity, and whether aryl groups could substitute for the palmitoyl group. The syntheses of
these analogues were accomplished (Scheme 1) using the strategy previously described by
us;17 as mentioned earlier, 6d, with a palmitoyl group (Scheme 1) was the point of
departure. Examination of this series of compounds showed a clear-cut and straightforward
SAR: 6d (palmitoyl) and 6e (stearoyl) were active in engaging hTLR2 (3.63 nM and 4.79
nM, respectively, Table 1), but entirely inactive in assays using mTLR2 (Fig. 1). The
shorter-chain analogues were completely inactive (Table 1). Aryl substituents were found to
abrogate activity as exemplified by the complete absence of activity in the biphenyl-4-
carboxylate (6f) and biphenyl-3-carboxylate (6g), as well as the p-terphenyl-4-carboxylate
(6h) derived analogues. The latter results were not unexpected given the dimensions of the
hydrophobic tunnel in the crystal structure of TLR2;26,28 however, we were also interested
in examining the possibility of these inactive analogues behaving as antagonists of TLR2,
since there is only one known report of a low-potency lanthionine-derived antagonist.29
None of the above-mentioned inactive compounds were antagonistic in homotypic (using
PAM2CS as stimulus) or heterotypic (using lipoteichoic acid30–32 as stimulus) assays in
mTLR2 and hTLR2 assays (data not shown).
Our previous SAR on the lipopeptides demonstrated the absolute requirement of the ester-
linked long-chain group, and of the importance of the orientation of the carbonyl group of
the ester; in these earlier studies, we had found that replacement of the long-chain
hydrocarbon functional group with polar poly-ether or polyamine moieties were not
tolerated.17 We were interested in examining a more conservative modification. We
hypothesized that the replacement of the palmitoyl group by a 2-(ditetradecylamino) acetate
fragment (10a, Scheme 2) may confer to the molecule dual hTLR2/mTLR2 activity by
mimicking PAM2CS. Our assumption was incorrect since both 10a and its mono-alkyl
homologue, 10b, were completely inactive (Table 1).
As mentioned earlier, N-palmitoylation of 6d (11g, Scheme 3) resulted in an unanticipated
loss of TLR2-agonistic activity (Table 1). We therefore examined in detail a variety of alkyl
and acyl substituents on the cysteine amine. The N-alkyl derivatives 11a (ethyl), 11b (octyl),
and 11c (hexadecyl) analogues (obtained by either reductive amination using appropriate
aldehydes for 11a and 11b, or by direct alkylation in the case of 11c using hexadecyl
bromide) were inactive (Table 1). In contradistinction, the short-chain N-acyl analogues
were found to be highly active, with a clear dependence on the chain-length: the N-acetyl
analogue 11d was found to be the most potent (1 nM), followed by the N-butyryl analogue
11e, and N-octanoyl compound 11f (3.8 nM). Further homologation (11g, palmitoyl)
resulted in complete loss of activity. Two points are to be noted; first, the active analogues
(11d–11f) retained specificity toward hTLR2 and displayed no agonistic activity in mTLR2;
second, while the EC50 of the lead compound (6d: 3.6 nM) is, at first glance, comparable to
that of the N-acetyl derivative (11d: 1 nM), the absolute magnitude of TLR2-induced
nuclear translocation of NF-κB is far greater for 11d and approaches that of PAM2CS (Fig.
1), indicating the higher potency of 11d.
The progressive decrease in activity with increasing N-acyl chain length strongly suggested
steric issues. We wanted to confirm this hypothesis and also evaluate replacements of the N-
acetyl group with functionalities differing in electron-withdrawing properties. The
trifluoroacetamido derivative 11h retains weaker activity (EC50: 4.5 nM, but low magnitude
of NF-κB activation, Fig. 1), while the trichloroacetamido analogue 11i is inactive;
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consistent with these results are the observations that the methanesulfonamide (11j),
trifluoromethanesulfonamide (11k) and p-toluenesulfonamide (11l) derivatives are all
inactive. Taken together, these results highlight the simultaneous influence of electronic and
steric effects of the substituents on the amine.
Given that the cysteine N-acyl substituents showed dramatic differences in activity as
described above, it was of interest to explore serine O-acyl substituents as well. The
syntheses of these analogues (Scheme 4) were straightforward, requiring the protection of
the cysteine amine as the t-butyl carbamate, followed by O-acylation with either anhydride
(14a) or acyl chlorides (14b, 14c). The activity of the O-acetyl analogue 14a is virtually
indistinguishable from that of 6d; progressive loss in activity was evident with increasing
acyl chain lengths (Fig. 1 and Table 1). As was observed for all of the compounds described
above, the O-acyl analogues were also found to be specific for hTLR2.
Given that N-acetylation appeared to specifically enhance TLR2-agonistic potency while
preserving specificity for human TLR2, it was interest to examine if this modification on an
inactive homologue of 6d that we had previously identified17 would also result in
augmented agonistic activity. The propylene-bridged 3-((R)-2-amino-3-((S)-3-hydroxy-1-
methoxy-1-oxopropan-2-ylamino)-3-oxopropylthio)propyl palmitate compound 15 was N-
acetylated to furnish 16 as depicted in Scheme 5. The N-acetylated derivative was found to
be active, albeit much weaker in potency than 11d (Table 1, Fig. 1), clearly emphasizing the
role of N-acetyl group in determining TLR2-agonistic potency, although the structural basis
for this observation remains to be elucidated.
Our continuing SAR studies on the TLR2-agonistic lipopeptide chemotype have led to the
identification of new analogues possessing strong TLR2-agonistic activity that is exquisitely
human TLR2-specific. It is being increasingly appreciated that significant differences
between murine and non-rodent species exist not only in receptor specificity to TLR ligands,
but also in the cellular responses to them. As has been observed with TLR4 ligands such as
taxol,33 lipid IVa, and E5531, a synthetic lipid A analogue,34 recent evidence suggests that
significant inter-species differences exist for TLR2 also, as exemplified by variations in
specificities for lipopeptide recognition in chimeric TLR constructs.35 Furthermore, the
coupling of these pattern recognition receptors to downstream adaptor molecules also appear
to be distinct as shown by disparities in clinical outcomes in humans with IRAK-4
(interleukin-1 receptor-associated kinase 4) deficiency versus the susceptibility to pathogens
in knockout mice.36 We do not yet understand the structural basis for this specificity, which
will have to await detailed crystallographic studies.
As discussed above, TLR2 agonists appear unique amongst all other TLR agonists in that
although the lipopeptides are devoid of any detectable pro-inflammatory activity in ex vivo
human blood models,25 or of local reactogenicity and pyrogenicity in rabbit models,18 it is
potently adjuvantic in murine models of immunization,25 suggesting that this chemotype
may be a safe and effective adjuvant. The human-specific TLR2-agonistic properties of the
monoacyl lipopeptides precludes its evaluation in murine models, and it remains to be
examined if non-rodent animal models (including non-human primates) would be suitable




All of the solvents and reagents used were obtained commercially and used as such unless
noted otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen
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atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under
reduced pressure using standard rotary evaporators. Flash column chromatography was
carried out using RediSep Rf ‘Gold’ high performance silica columns on CombiFlash Rf
instrument unless otherwise mentioned, while thin-layer chromatography was carried out on
silica gel CCM pre-coated aluminum sheets. Purity for all final compounds was confirmed
to be greater than 97% by LC-MS using a Zorbax Eclipse Plus 4.6 mm × 150 mm, 5 µm
analytical reverse phase C18 column with H2O-isopropanol or H2O-CH3CN gradients and an
Agilent ESI-TOF mass spectrometer (mass accuracy of 3 ppm) operating in the positive ion
(or negative ion, as appropriate) acquisition mode.
General procedure for the syntheses of compounds 5a–5g
Synthesis of Compound 5a: 2-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-
oxopropan-2-yl)amino)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)thio)ethyl
butyrate—To a solution of compound 4 (100 mg, 0.24 mmol) in anhydrous CH2Cl2 (5
mL), were added triethylamine (49 µL, 0.18 mmol) and 4-dimethylaminopyridine (DMAP,
3.0 mg, 0.024 mmol) and the reaction mixture was stirred at room temperature. After 10 min
butyryl chloride (30 µL, 0.28 mmol) was added and the reaction mixture was stirred for
further 30 min. The solvent was then removed using vacuum and the residue was purified
using column chromatography (5% MeOH/CH2Cl2) to obtain the compound 5a (99 mg,
85%). 1H NMR (500 MHz, CDCl3) δ 7.13 (d, J = 7.8 Hz, 1H), 5.44 (s, 1H), 4.65 (dt, J =
8.1, 3.0 Hz, 1H), 4.33 (d, J = 4.5 Hz, 1H), 4.24 (t, J = 6.6 Hz, 2H), 3.82 (dd, J = 9.1, 2.9 Hz,
1H), 3.74 (s, 3H), 3.57 (dd, J = 9.1, 3.2 Hz, 1H), 3.01 (dd, J = 13.9, 5.6 Hz, 1H), 2.92 (dd, J
= 13.9, 6.7 Hz, 1H), 2.84 (dd, J = 12.2, 6.1 Hz, 2H), 2.30 (t, J = 7.4 Hz, 2H), 1.65 (m, 2H),
1.45 (s, 9H), 1.13 (s, 9H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.61,
170.59, 170.50, 155.37, 80.40, 77.42, 77.42, 77.16, 76.91, 73.65, 63.15, 61.78, 53.84, 53.32,
52.57, 36.18, 34.98, 31.19, 28.43, 27.43, 18.50, 13.82. MS (ESI) calculated for
C22H40N2O8S, m/z 492.25, found 515.24 (M + Na)+.
Compounds 5b, 5c, 5e–5g were synthesized similarly as compound 5a. Compound 5d was
synthesized as published earlier.17
5b: 2-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-yl)amino)-2-((tert-
butoxycarbonyl)amino)-3-oxopropyl)thio)ethyl octanoate—(119 mg, 92%) 1H
NMR (500 MHz, CDCl3) δ 7.13 (d, J = 7.9 Hz, 1H), 5.44 (s, 1H), 4.65 (dt, J = 8.1, 3.0 Hz,
1H), 4.32 (s, 1H), 4.24 (t, J = 6.6 Hz, 2H), 3.82 (dd, J = 9.1, 2.9 Hz, 1H), 3.74 (s, 3H), 3.57
(dd, J = 9.1, 3.2 Hz, 1H), 3.01 (dd, J = 13.9, 5.5 Hz, 1H), 2.92 (dd, J = 13.9, 6.8 Hz, 1H),
2.83 (dd, J = 12.6, 6.3 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 1.61 (dd, J = 14.7, 7.4 Hz, 2H),
1.45 (s, 9H), 1.31 – 1.24 (m, 8H), 1.14 (s, 9H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 174.05, 170.84, 170.76, 155.61, 80.64, 73.91, 63.39, 62.03, 54.09, 53.57,
52.82, 35.22, 34.57, 32.04, 31.42, 29.48, 29.32, 28.69, 27.68, 25.28, 22.99, 14.47. MS (ESI)
calculated for C26H48N2O8S, m/z 548.31, found 571.31 (M + Na)+.
5c: 2-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-yl)amino)-2-((tert-
butoxycarbonyl)amino)-3-oxopropyl)thio)ethyl dodecanoate—(124 mg, 87%) 1H
NMR (500 MHz, CDCl3) δ 7.14 (d, J = 7.9 Hz, 1H), 5.44 (s, 1H), 4.65 (dt, J = 8.1, 3.0 Hz,
1H), 4.33 (d, J = 4.2 Hz, 1H), 4.23 (t, J = 6.6 Hz, 2H), 3.82 (dd, J = 9.1, 3.0 Hz, 1H), 3.74
(s, 3H), 3.57 (dd, J = 9.1, 3.2 Hz, 1H), 3.01 (dd, J = 13.9, 5.5 Hz, 1H), 2.92 (dd, J = 13.9,
6.8 Hz, 1H), 2.83 (dd, J = 12.6, 6.3 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 1.60 (dd, J = 14.6, 7.3
Hz, 2H), 1.45 (s, 9H), 1.30 – 1.23 (m, 16H), 1.14 (s, 9H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR
(126 MHz, CDCl3) δ 174.05, 170.84, 170.76, 155.61, 80.65, 73.91, 63.39, 62.03, 54.09,
53.57, 52.82, 35.22, 34.58, 32.30, 31.41, 30.00, 29.86, 29.73, 29.67, 29.54, 28.69, 27.68,
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25.28, 23.08, 14.52. MS (ESI) calculated for C30H56N2O8S, m/z 604.38, found 627.37 (M +
Na)+.
5e: 2-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-yl)amino)-2-((tert-
butoxycarbonyl)amino)-3-oxopropyl)thio)ethyl stearate—(142 mg, 87%). 1H
NMR (500 MHz, CDCl3) δ 7.13 (d, J = 7.9 Hz, 1H), 5.44 (s, 1H), 4.65 (dt, J = 8.1, 3.0 Hz,
1H), 4.33 (d, J = 4.5 Hz, 1H), 4.24 (t, J = 6.6 Hz, 2H), 3.82 (dd, J = 9.1, 2.9 Hz, 1H), 3.74
(s, 3H), 3.57 (dd, J = 9.1, 3.2 Hz, 1H), 3.01 (dd, J = 13.9, 5.5 Hz, 1H), 2.92 (dd, J = 13.9,
6.8 Hz, 1H), 2.83 (dd, J = 12.7, 6.4 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 1.63 – 1.58 (m, 2H),
1.46 (s, 9H), 1.30 – 1.22 (m, 28H), 1.14 (s, 9H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 174.05, 170.84, 170.76, 155.59, 80.65, 73.91, 63.38, 62.03, 54.09, 53.58,
52.82, 35.22, 34.58, 32.32, 31.42, 30.10, 30.06, 30.02, 29.88, 29.76, 29.69, 29.55, 28.69,
27.69, 25.28, 23.09, 14.53. MS (ESI) calculated for C36H68N2O8S, m/z 688.47, found
711.48 (M + Na)+.
5f: 2-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-yl)amino)-2-((tert-
butoxycarbonyl)amino)-3-oxopropyl)thio)ethyl [1,1'-biphenyl]-4-carboxylate—
(87 mg, 60%). 1H NMR (500 MHz, CDCl3) δ 8.11 (d, J = 8.5 Hz, 2H), 7.66 (d, J = 8.5 Hz,
2H), 7.63 (dd, J = 5.2, 3.3 Hz, 2H), 7.47 (t, J = 7.5 Hz, 2H), 7.40 (dt, J = 9.3, 4.3 Hz, 1H),
7.17 (d, J = 7.9 Hz, 1H), 5.48 (s, 1H), 4.67 (dt, J = 8.1, 3.0 Hz, 1H), 4.52 (t, J = 6.6 Hz, 2H),
4.38 (s, 1H), 3.83 (dd, J = 9.1, 2.9 Hz, 1H), 3.73 (s, 3H), 3.57 (dd, J = 9.1, 3.2 Hz, 1H), 3.09
(dd, J = 13.9, 5.5 Hz, 1H), 3.04 – 2.94 (m, 3H), 1.46 (s, 9H), 1.13 (s, 9H). 13C NMR (126
MHz, CDCl3) δ 170.61, 170.52, 166.42, 155.40, 145.94, 140.13, 130.38, 129.08, 128.79,
128.32, 127.43, 127.23, 80.44, 73.67, 63.79, 61.78, 53.88, 53.34, 52.58, 35.05, 31.28, 28.44,
27.43. MS (ESI) calculated for C31H42N2O8S, m/z 602.27, found 625.27 (M + Na)+.
5g: 2-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-yl)amino)-2-((tert-
butoxycarbonyl)amino)-3-oxopropyl)thio)ethyl [1,1'-biphenyl]-3-carboxylate—
(81 mg, 56%). 1H NMR (500 MHz, CDCl3) δ 8.28 (t, J = 1.6 Hz, 1H), 8.02 (d, J = 7.8 Hz,
1H), 7.79 (ddd, J = 7.7, 1.8, 1.2 Hz, 1H), 7.62 (d, J = 7.1 Hz, 2H), 7.52 (d, J = 7.7 Hz, 1H),
7.46 (dd, J = 9.9, 3.5 Hz, 2H), 7.38 (t, J = 7.4 Hz, 1H), 7.17 (d, J = 7.8 Hz, 1H), 5.48 (d, J =
3.4 Hz, 1H), 4.66 (dt, J = 8.1, 3.0 Hz, 1H), 4.52 (t, J = 6.7 Hz, 2H), 4.38 (d, J = 3.6 Hz, 1H),
3.82 (dd, J = 9.1, 2.9 Hz, 1H), 3.72 (s, 3H), 3.56 (dd, J = 9.1, 3.2 Hz, 1H), 3.08 (dd, J =
13.9, 5.4 Hz, 1H), 3.03 – 2.95 (m, 3H), 1.45 (s, 9H), 1.13 (s, 9H). 13C NMR (126 MHz,
CDCl3) δ 170.60, 170.50, 166.48, 155.39, 141.65, 140.21, 131.86, 130.61, 129.04, 128.57,
127.90, 127.32, 80.41, 73.66, 63.83, 61.76, 53.89, 53.34, 52.57, 35.05, 31.23, 28.43, 27.41.
MS (ESI) calculated for C31H42N2O8S, m/z 602.27, found 625.26 (M + Na)+.
General procedure for synthesis of compounds 6a–6g
Synthesis of Compound 6a: 2-(((R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-
oxopropan-2-yl)amino)-3-oxopropyl)thio)ethyl butyrate—Compound 5a (49 mg,
0.1 mmol) was dissolved in 2 mL of trifluoroacetic acid and stirred for 30 min, followed by
removal of the solvent by purging nitrogen and drying under vacuum to obtain the residue
which was further purified using column chromatography to obtain the trifluoroacetate salt
of compound 6a in quantitative yield (49 mg). 1H NMR (500 MHz, CDCl3) δ 8.52 (d, J =
7.7 Hz, 1H), 4.71 – 4.62 (m, 1H), 4.35 (t, J = 6.4 Hz, 1H), 4.28 – 4.17 (m, 2H), 3.97 – 3.90
(m, 1H), 3.87 (dd, J = 11.6, 5.1 Hz, 1H), 3.76 (s, 3H), 3.17 (dd, J = 14.4, 5.4 Hz, 1H), 3.02
(dd, J = 14.4, 7.1 Hz, 1H), 2.81 (t, J = 6.4 Hz, 2H), 2.31 (t, J = 7.4 Hz, 2H), 1.69 – 1.55 (m,
2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.40, 170.35, 168.39, 62.71,
61.83, 55.35, 52.91, 52.86, 36.14, 33.16, 30.90, 18.43, 13.71. MS (ESI) calculated for
C13H24N2O6S, m/z 336.14, found 337.15 (M + H)+.
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Compounds 6b, 6c, 6e–6g were synthesized similarly as compound 6a. Compound 6d was
synthesized as published earlier.17
6b: 2-(((R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-
oxopropyl)thio)ethyl octanoate—1H NMR (500 MHz, CDCl3) δ 8.49 (d, J = 7.7 Hz,
1H), 4.71 – 4.64 (m, 1H), 4.35 (t, J = 6.5 Hz, 1H), 4.26 – 4.18 (m, 2H), 3.96 – 3.90 (m, 1H),
3.86 (dd, J = 11.7, 5.2 Hz, 1H), 3.75 (s, 3H), 3.48 (s, 1H), 3.16 (dd, J = 14.5, 5.6 Hz, 1H),
3.01 (dd, J = 14.6, 7.2 Hz, 1H), 2.81 (t, J = 6.5 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 1.64-1.55
(m, 2H), 1.35 – 1.18 (m, 8H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
174.57, 170.31, 168.25, 62.64, 61.82, 55.38, 52.96, 52.82, 50.99, 34.30, 33.05, 31.78, 30.90,
29.21, 29.04, 24.97, 22.73, 14.19. MS (ESI) calculated for C17H32N2O6S, m/z 392.20,
found 393.21 (M + H)+.
6c: 2-(((R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-
oxopropyl)thio)ethyl dodecanoate—1H NMR (500 MHz, CDCl3) δ 8.49 (d, J = 7.3
Hz, 1H), 4.68 (s, 1H), 4.36 (s, 1H), 4.23 (t, J = 6.0 Hz, 2H), 3.93 (d, J = 9.5 Hz, 1H), 3.86
(dd, J = 11.1, 4.7 Hz, 1H), 3.76 (s, 3H), 3.16 (dd, J = 14.3, 5.2 Hz, 1H), 3.02 (dd, J = 14.2,
6.9 Hz, 1H), 2.81 (t, J = 6.4 Hz, 2H), 2.31 (t, J = 7.7 Hz, 2H), 1.59 (dd, J = 14.3, 7.2 Hz,
2H), 1.31 – 1.22 (m, 16H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.83,
170.54, 168.51, 62.89, 62.07, 55.65, 53.22, 53.07, 34.57, 33.29, 32.31, 31.15, 30.03, 30.02,
29.90, 29.75, 29.69, 29.55, 25.24, 23.08, 14.52. MS (ESI) calculated for C21H40N2O6S, m/z
448.26, found 449.27 (M + H)+.
6e: 2-(((R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-
oxopropyl)thio)ethyl stearate—1H NMR (500 MHz, CDCl3) δ 8.47 (d, J = 7.6 Hz, 1H),
4.72 – 4.64 (m, 1H), 4.35 (t, J = 6.3 Hz, 1H), 4.24 – 4.16 (m, 2H), 3.94 (d, J = 8.9 Hz, 1H),
3.86 (dd, J = 11.6, 5.1 Hz, 1H), 3.76 (s, 3H), 3.16 (dd, J = 14.4, 5.3 Hz, 1H), 3.03 – 2.97 (m,
1H), 2.81 (t, J = 6.4 Hz, 2H), 2.31 (t, J = 7.7 Hz, 2H), 1.59 (dd, J = 14.3, 7.1 Hz, 2H), 1.39 –
1.09 (m, 28H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.43, 170.15,
168.12, 62.49, 61.70, 55.26, 52.83, 52.69, 34.18, 32.94, 31.94, 30.79, 29.73, 29.71, 29.68,
29.54, 29.38, 29.32, 29.18, 24.85, 22.70, 14.13. MS (ESI) calculated for C27H52N2O6S, m/z
532.35, found 533.37 (M + H)+.
6f: 2-(((R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-
oxopropyl)thio)ethyl [1,1'-biphenyl]-4-carboxylate—1H NMR (500 MHz, CDCl3) δ
8.57 (d, J = 7.4 Hz, 1H), 8.02 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H), 7.55 – 7.52 (m,
2H), 7.40 (t, J = 7.4 Hz, 2H), 7.36 – 7.31 (m, 1H), 4.72 – 4.67 (m, 1H), 4.50 – 4.42 (m, 3H),
3.94 (d, J = 9.2 Hz, 1H), 3.87 (dd, J = 11.4, 4.7 Hz, 1H), 3.65 (s, 3H), 3.25 (dd, J = 14.3, 5.1
Hz, 1H), 3.10 (dd, J = 14.3, 6.9 Hz, 1H), 2.95 (t, J = 6.4 Hz, 2H). 13C NMR (126 MHz,
CDCl3) δ 170.59, 168.60, 167.20, 146.33, 140.15, 130.62, 129.31, 128.63, 128.60, 127.62,
127.45, 63.57, 62.12, 55.67, 53.18, 51.27, 33.42, 31.25. MS (ESI) calculated for
C22H26N2O6S, m/z 446.15, found 447.16 (M + H)+.
6g: 2-(((R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-
oxopropyl)thio)ethyl [1,1'-biphenyl]-3-carboxylate—1H NMR (500 MHz, CDCl3) δ
8.54 (d, J = 7.5 Hz, 1H), 8.21 (s, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.72 (d, J = 7.8 Hz, 1H),
7.56 (d, J = 7.2 Hz, 2H), 7.42 (dt, J = 13.5, 7.8 Hz, 3H), 7.33 (t, J = 7.4 Hz, 1H), 4.71 – 4.64
(m, 1H), 4.48 – 4.42 (m, 3H), 3.92 (d, J = 9.2 Hz, 1H), 3.85 (dd, J = 11.5, 4.9 Hz, 1H), 3.63
(s, 3H), 3.48 (s, 2H), 3.23 (dd, J = 14.4, 5.3 Hz, 1H), 3.08 (dd, J = 14.3, 6.9 Hz, 1H), 2.93 (t,
J = 6.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 170.55, 168.54, 167.25, 141.87, 140.27,
132.28, 130.50, 129.33, 129.28, 128.84, 128.71, 128.18, 127.50, 63.56, 62.10, 55.67, 53.16,
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51.27, 33.38, 31.21. MS (ESI) calculated for C22H26N2O6S, m/z 446.15, found 447.16 (M +
H)+.
Synthesis of Compound 6h: 2-(((R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-
oxopropan-2-yl)amino)-3-oxopropyl)thio)ethyl [1,1'-biphenyl]-3-carboxylate—
To a solution of p-terphenyl-4-carboxylic acid (33 mg, 0.12 mmol) and compound 4 (100
mg, 0.24 mmol) in anhydrous dimethylformamide (DMF), were added triethylamine (33 µL,
0.24 mmol), DMAP (2.9 mg, 0.024 mmol) and O-benzotriazole-N,N,N’,N’-tetramethyl-
uronium hexafluorophosphate (HBTU, 55 mg, 0.144 mmol) and the reaction mixture was
stirred at room temperature for 14 h, followed by removal of the solvent under reduced
pressure. The crude was then dissolved in ethyl acetate and washed with water. The organic
fraction was dried over anhydrous sodium sulfate, filtered, concentrated and purified using
column chromatography (5% MeOH/CH2Cl2) to obtain the compound 5h. The product
obtained was dissolved in 2 mL of trifluoroacetic acid and stirred for 30 min, followed by
removal of the solvent by purging nitrogen and drying under vacuum to obtain the residue
which was further purified using column chromatography to obtain the trifluoroacetate salt
of compound 6h (37 mg, 59%). 1H NMR (500 MHz, MeOD) δ 8.14 (d, J = 8.5 Hz, 2H),
7.83 (d, J = 8.5 Hz, 2H), 7.81 – 7.74 (m, 2H), 7.68 (dd, J = 8.3, 1.1 Hz, 1H), 7.46 (t, J = 7.7
Hz, 1H), 7.37 (t, J = 7.4 Hz, 1H), 4.62 (t, J = 5.0 Hz 1H), 4.59 – 4.53 (m, 1H), 4.17 (dd, J =
8.8, 4.7 Hz, 1H), 3.97 (dd, J = 11.2, 4.8 Hz, 1H), 3.85 (dd, J = 11.2, 3.8 Hz, 1H), 3.74 (s,
3H), 3.35 (d, J = 4.6 Hz, 1H), 3.07 (td, J = 6.5, 2.5 Hz, 2H), 3.02 (dd, J = 14.7, 8.8 Hz,
1H). 13C NMR (126 MHz, MeOD) δ 171.67, 169.09, 167.76, 146.80, 142.49, 141.63,
139.84, 131.30, 129.98, 129.89, 128.69, 128.66, 128.61, 128.01, 127.92, 64.82, 62.57,
56.41, 53.59, 53.00, 34.29, 31.68. MS (ESI) calculated for C28H30N2O6S, m/z 522.18,
found 523.19 (M + H)+.
Syntheses of methyl 2-(ditetradecylamino)acetate (8a) and methyl 2-((tert-
butoxycarbonyl)(tetradecyl)amino)acetate (8b)—To a solution of glycine methyl
ester 7 (1.0 g, 8 mmol) in DMF (5 mL) triethylamine (4.5 mL, 32 mmol) was added,
followed by 1-bromotetradecane (3.6 mL, 12 mmol) and the reaction mixture was stirred at
room temperature for 18 h. The solvent was evaporated, water (50 mL) was added and the
product was extracted in CH2Cl2 (100 mL). The organic layer was dried over sodium sulfate
and evaporated to afford a mixture of methyl 2-(tetradecylamino)acetate and methyl 2-
(ditetradecylamino)acetate. Di-tert-butyl dicarbonate (1.0 g) was added to the solution of
this crude mixture in anhydrous CH2Cl2 (10 mL) followed by triethylamine (0.7 mL, 5.25
mmol) was added and the reaction mixture was stirred at room temperature for 1 h. The
solvent was removed and the product was column purified to furnish compound 8a (330 mg,
9%) and compound 8b (1.01 g, 33%). Spectroscopic evidence for two conformers for 8b
was observed in both 1H and 13C NMR.
8a—1H NMR (500 MHz, CDCl3) δ 3.69 (s, 3H), 3.32 (s, 2H), 2.53 (dd, J = 8.6, 6.7 Hz,
4H), 1.46 – 1.39 (m, 4H), 1.35 – 1.15 (m, 44H), 0.88 (t, J = 7.0 Hz, 6H). 13C NMR (126
MHz, CDCl3) δ 172.39, 55.26, 54.71, 51.54, 32.08, 29.85, 29.84, 29.83, 29.81, 29.79, 29.73,
29.52, 27.56, 27.53, 22.85, 14.28. MS (ESI) calculated for C31H63NO2, m/z 481.49, found
482.67 (M + H)+.
8b—1H NMR (500 MHz, CDCl3) δ 3.95 (s, 1H), 3.86 (s, 1H), 3.73 (d, J = 2.6 Hz, 3H), 3.25
(dt, J = 19.4, 7.5 Hz, 2H), 1.42–1.50 (m, 11H), 1.34 – 1.19 (m, 22H), 0.88 (t, J = 7.0 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 170.91, 170.81, 156.02, 155.27, 80.16, 80.13, 52.11,
52.05, 49.27, 48.60, 48.49, 48.43, 32.06, 29.83, 29.81, 29.79, 29.75, 29.54, 29.50, 29.45,
28.50, 28.44, 28.39, 28.27, 26.93, 26.86, 22.83, 14.27. MS (ESI) calculated for C22H43NO4,
m/z 385.32, found 386.33 (M + H)+.
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Synthesis of 2-(ditetradecylamino)acetic acid (9a)—Compound 8a (275 mg, 0.57
mmol) was dissolved in tetrahydrofuran (THF, 10 mL) and LiOH (68 mg, 2.85 mmol) in 2
mL of H2O was added and the reaction mixture was stirred at room temperature for 18 h.
The solvent was evaporated, water added, the pH of the aqueous layer was rendered acidic
by the addition of 1N HCl, and the product was extracted in CH2Cl2. The organic layer was
dried over anhydrous sodium sulfate, evaporated, and column purified to afford compound
9a as white solid (250 mg, 93%). 1H NMR (500 MHz, CDCl3) δ 3.29 (s, 2H), 3.13 (s, 1H),
2.72 – 2.46 (m, 4H), 1.47 (m, 4H), 1.19 (m, 44H), 0.81 (t, J = 6.9 Hz, 6H). 13C NMR (126
MHz, CDCl3) δ 174.66, 58.26, 54.51, 31.94, 29.72, 29.71, 29.68, 29.64, 29.63, 29.51, 29.39,
27.43, 25.00, 22.70, 14.09. MS (ESI) calculated for C30H61NO2, m/z 467.47, found 468.49
(M + H)+. Compound 9b was synthesized similarly as compound 9a.
9b: 2-((tert-butoxycarbonyl)(tetradecyl)amino)acetic acid—Spectroscopic
evidence for two conformers was observed in both 1H and 13C NMR. 1H NMR (500 MHz,
CDCl3) δ 3.88 (d, J = 9.7 Hz, 2H), 3.30 – 3.18 (m, 2H), 1.52-1.38 (m, 11H), 1.32 – 1.20 (m,
22H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 175.85, 175.28, 156.82,
155.32, 80.83, 80.31, 49.70, 49.16, 48.82, 48.29, 32.07, 29.84, 29.82, 29.81, 29.76, 29.68,
29.64, 29.57, 29.51, 29.46, 28.50, 28.39, 28.35, 28.25, 26.95, 26.84, 22.84, 14.28. MS (ESI)
calculated for C21H41NO4, m/z 371.30, found 394.30 (M + Na)+.
Synthesis of (S)-methyl 2-((R)-2-amino-3-((2-(2-
(ditetradecylamino)acetoxy)ethyl) thio)propanamido)-3-hydroxypropanoate
(10a)—To the solution of compound 4 (80 mg, 0.189 mmol) and 9a (177 mg, 0.379 mmol)
in dry CH2Cl2 (5 mL) N-methylmorpholine (41 µL, 0.379 mmol) and DMAP (9.0 mg, 0.076
mmol) were added, and the reaction mixture was stirred in an ice bath. After 20 min 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI.HCl, 58 mg, 0.379
mmol) was added and the reaction mixture was stirred at room temperature for 18 h. 50 mL
of CH2Cl2 was added to the reaction mixture and the organic layer was washed with water,
brine, dried over anhydrous sodium sulfate and evaporated. The crude product was further
column purified to furnish the ester intermediate N-Boc, O-tBu protected 10a. The product
obtained was dissolved in 4 mL of trifluoroacetic acid and stirred for 30 min, followed by
removal of the solvent by purging nitrogen and drying under vacuum to obtain the residue
which was further purified using column chromatography to obtain the trifluoroacetate salt
of compound 10a in quantitative yield. 1H NMR (500 MHz, MeOD) δ 4.60 (t, J = 4.1 Hz,
1H), 4.48 (dtd, J = 17.9, 11.7, 6.2 Hz, 2H), 4.19 (s, 2H), 4.15 (dd, J = 8.4, 4.8 Hz, 1H), 3.97
(dd, J = 11.3, 4.6 Hz, 1H), 3.84 (dd, J = 11.3, 3.7 Hz, 1H), 3.76 (s, 3H), 3.28 (dd, J = 14.8,
4.9 Hz, 1H), 3.20 (dd, J = 9.6, 7.1 Hz, 4H), 3.03 – 2.87 (m, 3H), 1.72 (s, 4H), 1.45-1.25 (m,
44H), 0.90 (t, J = 7.0 Hz, 6H). 13C NMR (126 MHz, MeOD) δ 171.87, 169.24, 167.79,
66.48, 62.57, 56.35, 55.98, 54.39, 53.31, 53.01, 34.00, 33.09, 30.81, 30.79, 30.78, 30.76,
30.64, 30.51, 30.49, 30.19, 27.56, 25.03, 23.75, 14.45. MS (ESI) calculated for
C39H77N3O6S, m/z 715.55, found 716.59 (M + H)+.
Compound 10b was synthesized similarly as compound 10a.
10b: (S)-methyl 2-((R)-2-amino-3-((2-(2-
(tetradecylamino)acetoxy)ethyl)thio)propanamido)-3-hydroxypropanoate—1H
NMR (400 MHz, CDCl3) δ 8.26 (d, J = 7.7 Hz, 1H), 4.63 (dt, J = 7.6, 3.8 Hz, 1H), 4.36 –
4.24 (m, 2H), 3.95 (ddd, J = 17.8, 11.2, 3.8 Hz, 2H), 3.80 (s, 3H), 3.67 – 3.58 (m, 1H), 3.44
(s, 2H), 3.05 (dd, J = 13.6, 4.3 Hz, 1H), 2.95 (dd, J = 13.6, 6.9 Hz, 1H), 2.81 (t, J = 6.6 Hz,
2H), 2.63 – 2.55 (m, 2H), 1.72 (bs, 4H), 1.49 (m, 2H), 1.29 – 1.23 (m, 22H), 0.88 (t, J = 6.8
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.78, 172.27, 170.90, 63.76, 63.14, 54.87, 54.12,
52.87, 50.86, 49.74, 37.99, 32.07, 31.00, 29.96, 29.84, 29.83, 29.82, 29.80, 29.77, 29.74,
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29.66, 29.51, 27.35, 22.84, 14.28. MS (ESI) calculated for C25H49N3O6S, m/z 519.33,
found 520.35 (M + H)+.
Synthesis of Compound 11a: 2-(((R)-2-(ethylamino)-3-(((S)-3-hydroxy-1-
methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl)thio)ethyl palmitate—To a
solution of compound 6d (50 mg, 0.081 mmol) in anhydrous CH2Cl2 were added
acetaldehyde (3.5 mg, 0.081 mmol), 4 drops of acetic acid and macroporous polystyrene-
bound cyanoborohydride (73 mg, 0.162 mmol). The reaction mixture was stirred for 2 h and
then filtered to remove the solid resin. The filtrate was evaporated under vacuum to obtain
the residue, which was purified using column chromatography (4% MeOH/CH2Cl2),
yielding compound 11a (8 mg, 20%). 1H NMR (500 MHz, CDCl3) δ 8.28 (d, J = 7.7 Hz,
1H), 4.64 (dt, J = 7.7, 3.8 Hz, 1H), 4.22 (t, J = 6.7 Hz, 2H), 4.01 – 3.90 (m, 2H), 3.80 (s,
3H), 3.28 (dd, J = 8.2, 3.9 Hz, 1H), 3.10 (dd, J = 13.5, 3.9 Hz, 1H), 2.84 – 2.71 (m, 3H),
2.68 (qd, J = 7.1, 2.9 Hz, 2H), 2.32 (t, J = 7.6 Hz, 2H), 2.08 (s, 2H), 1.66 – 1.54 (m, 2H),
1.35 – 1.21 (m, 24H), 1.15 (t, J = 7.1 Hz, 3H), 0.87 (d, J = 7.1 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 173.93, 173.55, 170.77, 63.50, 63.05, 61.55, 54.72, 52.88, 43.30, 35.83,
34.32, 32.07, 30.93, 29.84, 29.83, 29.80, 29.76, 29.62, 29.51, 29.42, 29.28, 25.04, 22.84,
15.50, 14.28. MS (ESI) calculated for C27H52N2O6S, m/z 532.35, found 533.37 (M + H)+.
Compound 11b was synthesized similarly as compound 11a.
11b: 2-(((R)-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-
(octylamino)-3-oxopropyl)thio)ethyl palmitate—(10 mg, 20%). 1H NMR (500 MHz,
CDCl3) δ 8.26 (d, J = 7.7 Hz, 1H), 4.63 (dt, J = 7.7, 3.8 Hz, 1H), 4.22 (t, J = 6.7 Hz, 2H),
4.03 – 3.91 (m, 2H), 3.79 (s, 3H), 3.30 (dd, J = 7.8, 3.5 Hz, 1H), 3.10 (dd, J = 13.5, 3.9 Hz,
1H), 2.86 – 2.71 (m, 3H), 2.63 (td, J = 7.2, 2.2 Hz, 2H), 2.32 (t, J = 7.6 Hz, 2H), 2.05 (s,
2H), 1.67 – 1.55 (m, 2H), 1.51 (dd, J = 14.2, 7.1 Hz, 2H), 1.37 – 1.19 (m, 34H), 0.92 – 0.82
(m, 6H). 13C NMR (126 MHz, CDCl3) δ 173.94, 173.41, 170.67, 63.47, 63.05, 61.57, 54.78,
52.85, 48.95, 35.71, 34.32, 32.07, 31.98, 30.94, 30.19, 29.84, 29.81, 29.77, 29.62, 29.51,
29.43, 29.41, 29.29, 27.32, 25.04, 22.84, 22.81, 14.28, 14.25. MS (ESI) calculated for
C33H64N2O6S, m/z 616.45, found 617.46 (M + H)+.
Synthesis of Compound 11c: 2-(((R)-2-(hexadecylamino)-3-(((S)-3-hydroxy-1-
methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl)thio)ethyl palmitate—To a
solution of compound 6d (100 mg, 0.162 mmol) in anhydrous DMF, triethylamine (56 µL,
0.405 mmol) was added, followed by 1-bromohexadecane (123 µL, 0.405 mmol). The
reaction mixture was stirred at room temperature for 14 h. DMF was evaporated at 50 °C
and the crude product obtained was purified using column chromatography to give
compound 11c (18 mg, 15%) as white solid. 1H NMR (400 MHz, CDCl3) δ 8.26 (d, J = 7.7
Hz, 1H), 4.63 (dt, J = 7.6, 3.7 Hz, 1H), 4.22 (t, J = 6.7 Hz, 2H), 4.00 – 3.90 (m, 2H), 3.80 (s,
3H), 3.26 (dd, J = 8.1, 3.7 Hz, 1H), 3.09 (dd, J = 13.5, 3.7 Hz, 1H), 2.83 – 2.72 (m, 3H),
2.61 (t, J = 7.0 Hz, 2H), 2.32 (t, J = 7.6 Hz, 2H), 1.88 (bs, 2H), 1.65 – 1.54 (m, 2H), 1.54 –
1.45 (m, 2H), 1.25 (s, 50H), 0.88 (t, J = 6.7 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ
173.90, 173.60, 170.69, 63.51, 63.06, 61.66, 54.76, 52.85, 49.01, 35.82, 34.32, 32.07, 30.92,
30.30, 29.86, 29.85, 29.81, 29.78, 29.70, 29.63, 29.51, 29.43, 29.29, 27.36, 25.04, 22.84,
14.28. MS (ESI) calculated for C41H80N2O6S, m/z 728.57, found 729.58 (M + H)+.
Synthesis of Compound 11d: 2-(((R)-2-acetamido-3-(((S)-3-hydroxy-1-
methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl)thio)ethyl palmitate—To a
solution of compound 6d (50 mg, 0.081 mmol) in anhydrous CH2Cl2 were added
triethylamine (17 µL, 0.121 mmol) and acetic anhydride (8 µL, 0.081 mmol). The reaction
mixture was stirred for 2 h. The solvent was removed under vacuum to obtain the residue
which was purified using column chromatography (6% MeOH/CH2Cl2), furnishing
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compound 11d (35 mg, 79%). 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 7.7 Hz, 1H), 6.63
(d, J = 7.1 Hz, 1H), 4.67 – 4.57 (m, 2H), 4.37 – 4.17 (m, 2H), 4.01 – 3.90 (m, 2H), 3.79 (s,
3H), 3.26 (t, J = 6.3 Hz, 1H), 2.96 (dd, J = 6.4, 3.6 Hz, 2H), 2.83 (t, J = 6.6 Hz, 2H), 2.32 (t,
J = 7.6 Hz, 2H), 2.05 (s, 3H), 1.60 (dd, J = 14.4, 7.2 Hz, 2H), 1.25 (s, 24H), 0.87 (t, J = 6.8
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.32, 170.95, 170.58, 170.55, 62.88, 62.76,
55.18, 52.93, 52.89, 34.56, 34.39, 32.06, 31.30, 29.84, 29.80, 29.76, 29.62, 29.50, 29.42,
29.29, 25.02, 23.23, 22.84, 14.27. MS (ESI) calculated for C27H50N2O7S, m/z 546.33,
found 547.35 (M + H)+.
Compounds 11h, 11j and 11k were synthesized similarly as compound 11d.
11h: 2-(((R)-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-oxo-2-
(2,2,2-trifluoroacetamido)propyl)thio)ethyl palmitate—(10 mg, 21%). 1H NMR
(500 MHz, CDCl3) δ 7.59 (d, J = 7.0 Hz, 1H), 7.50 (d, J = 7.8 Hz, 1H), 4.72 – 4.63 (m, 2H),
4.40 – 4.30 (m, 1H), 4.27 (dd, J = 12.0, 5.7 Hz, 1H), 4.00 (ddd, J = 54.9, 11.5, 3.3 Hz, 2H),
3.80 (s, 3H), 2.99 (t, J = 6.2 Hz, 2H), 2.92 – 2.80 (m, 2H), 2.77 (s, 1H), 2.38 – 2.26 (m, 2H),
1.66 – 1.55 (m, 2H), 1.38 – 1.18 (m, 24H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz,
CDCl3) δ 174.69, 170.38, 168.95, 157.74, 157.44, 157.13, 156.83, 119.13, 116.85, 114.56,
112.28, 62.81, 62.75, 55.14, 53.06, 52.77, 34.51, 34.41, 32.06, 31.38, 29.84, 29.83, 29.80,
29.76, 29.61, 29.50, 29.40, 29.27, 24.98, 22.83, 14.27. MS (ESI) calculated for
C27H47F3N2O7S, m/z 600.31, found 601.31 (M + H)+ and 618.34 (M + NH4+).
11j: 2-(((R)-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-
(methylsulfonamido)-3-oxopropyl)thio)ethyl palmitate—(7 mg, 15%). 1H NMR
(400 MHz, CDCl3) δ 7.43 (d, J = 7.6 Hz, 1H), 5.60 (d, J = 7.9 Hz, 1H), 4.71 – 4.60 (m, 1H),
4.24 (dt, J = 14.1, 6.4 Hz, 3H), 4.10 – 3.92 (m, 2H), 3.80 (s, 3H), 3.09 (s, 3H), 3.05 (t, J =
5.7 Hz, 2H), 2.82 (t, J = 6.6 Hz, 2H), 2.71 (s, 1H), 2.33 (t, J = 7.6 Hz, 2H), 1.60 (q, J = 7.3
Hz, 3H), 1.28 – 1.25 (m, 23H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ
174.49, 170.46, 170.05, 62.83, 62.78, 56.26, 55.17, 53.06, 41.84, 35.62, 34.40, 32.07, 31.27,
29.84, 29.81, 29.77, 29.63, 29.51, 29.41, 29.29, 25.02, 22.84, 14.27. MS (ESI) calculated for
C26H50N2O8S2, m/z 582.30, found 583.31 (M + H)+.
11k: 2-(((R)-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-oxo-2-
(trifluoromethylsulfonamido)propyl)thio)ethyl palmitate—(39 mg, 78%). 1H NMR
(500 MHz, CDCl3) δ 7.60 (d, J = 7.9 Hz, 1H), 4.75 – 4.64 (m, 1H), 4.36 (t, J = 6.4 Hz, 1H),
4.28 – 4.20 (m, 2H), 4.05 (dd, J = 11.5, 3.5 Hz, 1H), 3.92 (dd, J = 11.5, 3.3 Hz, 1H), 3.79 (s.
3H), 3.07 – 2.94 (m, 2H), 2.86 – 2.72 (m, 2H), 2.33 (t, J = 7.6 Hz, 2H), 1.59 (dd, J = 14.5,
7.2 Hz, 2H), 1.33 – 1.18 (m, 26H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
174.71, 170.56, 169.23, 123.42, 120.87, 118.32, 115.77, 62.79, 62.75, 57.35, 54.99, 53.13,
35.73, 34.37, 32.06, 31.29, 29.83, 29.79, 29.76, 29.61, 29.50, 29.40, 29.26, 24.97, 22.83,
14.26. MS (ESI) calculated for C26H47F3N2O8S2, m/z 636.27, found 637.28 (M + H)+ and
654.31 (M + NH4+).
Synthesis of Compound 11e: 2-(((R)-2-butyramido-3-(((S)-3-hydroxy-1-
methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl)thio)ethyl palmitate—To a
solution of compound 6d (50 mg, 0.081 mmol) in pyridine (1 mL), butyryl chloride (10.2
µL, 0.097 mmol) was added and the reaction mixture was stirred at room temperature for 1
h. The volatiles were removed by evaporation, and the crude product obtained was purified
using column chromatography (10 % MeOH/CH2Cl2) to obtain compound 11e as a white
solid (35 mg, 76%). 1H NMR (500 MHz, CDCl3) δ 7.42 (d, J = 7.7 Hz, 1H), 6.59 (d, J = 7.1
Hz, 1H), 4.63 (dt, J = 8.8, 5.0 Hz, 2H), 4.35 – 4.19 (m, 2H), 3.96 (dt, J = 11.5, 8.0 Hz, 2H),
3.78 (s, 3H), 3.02 – 2.90 (m, 2H), 2.84 (t, J = 6.6 Hz, 2H), 2.32 (t, J = 7.6 Hz, 2H), 2.27 –
2.19 (m, 2H), 1.73 – 1.55 (m, 5H), 1.35 – 1.19 (m, 24H), 0.95 (t, J = 7.4 Hz, 3H), 0.87 (t, J
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= 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.31, 173.88, 170.62, 170.57, 62.93,
62.77, 55.19, 52.91, 52.71, 38.45, 34.54, 34.39, 32.06, 31.31, 29.83, 29.80, 29.76, 29.62,
29.50, 29.42, 29.29, 25.02, 22.83, 19.13, 14.27, 13.84. MS (ESI) calculated for
C29H54N2O7S, m/z 574.37, found 575.38 (M + H)+.
Compounds 11f and 11g were synthesized similarly as compound 11e.
11f: 2-(((R)-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-
octanamido-3-oxopropyl)thio)ethyl palmitate—(32 mg, 62%). 1H NMR (500 MHz,
CDCl3) δ 7.39 (d, J = 7.6 Hz, 1H), 6.55 (d, J = 7.0 Hz, 1H), 4.66 – 4.55 (m, 2H), 4.35 – 4.17
(m, 2H), 4.03 – 3.89 (m, 2H), 3.79 (s, 3H), 3.19 (s, 1H), 2.96 (qd, J = 13.9, 6.4 Hz, 2H), 2.84
(t, J = 6.6 Hz, 2H), 2.32 (t, J = 7.6 Hz, 2H), 2.26 – 2.22 (m, 2H), 1.77 (s, 1H), 1.61 (dd, J =
14.5, 7.5 Hz, 4H), 1.34 – 1.19 (m, 31H), 0.90 – 0.83 (m, 6H). 13C NMR (126 MHz, CDCl3)
δ 174.33, 174.01, 170.60, 170.56, 62.93, 62.79, 55.20, 52.92, 52.73, 36.62, 34.54, 34.40,
32.07, 31.80, 31.34, 29.84, 29.80, 29.77, 29.63, 29.51, 29.43, 29.34, 29.30, 29.12, 25.68,
25.03, 22.84, 22.75, 14.27, 14.21. MS (ESI) calculated for C33H62N2O7S, m/z 630.43,
found 631.44 (M + H)+.
11g: 2-(((R)-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-oxo-2-
palmitamidopropyl)thio)ethyl palmitate—(41 mg, 68%). 1H NMR (500 MHz, CDCl3)
δ 7.37 (d, J = 7.6 Hz, 1H), 6.55 (d, J = 7.0 Hz, 1H), 4.61 (ddd, J = 19.9, 10.3, 5.0 Hz, 2H),
4.33 (dt, J = 11.4, 6.7 Hz, 1H), 4.24 (dt, J = 11.4, 6.4 Hz, 1H), 3.97 (qd, J = 11.6, 3.5 Hz,
2H), 3.79 (s, 3H), 2.95 (ddd, J = 30.5, 14.0, 6.5 Hz, 2H), 2.85 (t, J = 6.6 Hz, 2H), 2.34 –
2.30 (m, 2H), 2.27 – 2.21 (m, 2H), 1.62 (dd, J = 14.6, 7.3 Hz, 4H), 1.29 – 1.23 (m, 49H),
0.87 (t, J = 7.0 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 174.38, 174.01, 170.63, 170.53,
62.94, 62.80, 55.21, 52.94, 52.76, 36.63, 34.48, 34.41, 32.07, 31.36, 29.85, 29.81, 29.79,
29.78, 29.76, 29.65, 29.64, 29.62, 29.52, 29.49, 29.43, 29.41, 29.30, 25.69, 25.03, 22.84,
14.28. MS (ESI) calculated for C41H78N2O7S, m/z 742.55, found 743.56 (M + H)+.
Synthesis of Compound 11i: 2-(((R)-3-(((S)-3-hydroxy-1-methoxy-1-
oxopropan-2-yl)amino)-3-oxo-2-(2,2,2-trichloroacetamido)propyl)thio)ethyl
palmitate—To a solution of compound 6d (40 mg, 0.079 mmol) in anhydrous CH2Cl2
were added triethylamine (11 µL, 0.079 mmol), trichloroacetic acid (13 mg, 0.079 mmol),
EDCI.HCl (19 mg, 0.095 mmol) and a catalytic amount of 1-hydroxybenzotriazole (HOBt).
The reaction mixture was stirred for 2 h and the solvent was then removed under vacuum.
The residue was purified using column chromatography (5% MeOH/ CH2Cl2) to obtain
compound 11i (6 mg, 12%). 1H NMR (500 MHz, DMSO) δ 8.61 (d, J = 7.6 Hz, 1H), 5.16 (t,
J = 5.4 Hz, 1H), 4.57 (dd, J = 10.4, 4.0 Hz, 1H), 4.38 (dt, J = 7.7, 4.7 Hz, 1H), 4.14 (tt, J =
12.9, 5.5 Hz, 2H), 3.75 (dt, J = 10.7, 4.0 Hz, 1H), 3.63 (s, 3H), 3.03 (dd, J = 13.9, 4.0 Hz,
1H), 2.94 (dd, J = 13.9, 10.5 Hz, 1H), 2.81 (qd, J = 13.9, 7.2 Hz, 2H), 2.28 (t, J = 7.4 Hz,
2H), 1.54 – 1.47 (m, 2H), 1.23 (s, 24H), 0.85 (t, J = 6.9 Hz, 3H).13C NMR (126 MHz,
DMSO) δ 172.80, 170.72, 169.26, 161.53, 92.55, 63.00, 61.09, 54.79, 54.46, 51.98, 33.42,
33.20, 31.32, 29.81, 29.06, 29.03, 29.00, 28.90, 28.73, 28.71, 28.45, 24.45, 22.13, 13.99. MS
(ESI) calculated for C27H47Cl3N2O7S, m/z 648.22, found 649.22 (M+H)+ and 666.25 (M +
NH4+).
Synthesis of Compound 11l: 2-(((R)-3-(((S)-3-hydroxy-1-methoxy-1-
oxopropan-2-yl)amino)-2-(4-methylphenylsulfonamido)-3-oxopropyl)thio)ethyl
palmitate—To a solution of compound 6d (40 mg, 0.079 mmol) in anhydrous CH2Cl2
were added triethylamine (11 µL, 0.079 mmol) and 4-methylbenzene-1-sulfonyl chloride
(15 mg, 0.079 mmol). The reaction mixture was stirred for 2 h and the solvent was then
removed under vacuum. The residue was purified using column chromatography (5%
MeOH/ CH2Cl2) to obtain compound 11l (25 mg, 48%). 1H NMR (500 MHz, CDCl3) δ 7.78
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(d, J = 8.3 Hz, 2H), 7.46 (d, J = 7.3 Hz, 1H), 7.33 (d, J = 8.0 Hz, 2H), 5.82 (d, J = 7.6 Hz,
1H), 4.53 (dt, J = 7.2, 3.6 Hz, 1H), 4.13 (td, J = 6.5, 1.6 Hz, 2H), 3.99 – 3.90 (m, 2H), 3.90 –
3.81 (m, 1H), 3.78 (s, 3H), 3.02 (dd, J = 14.2, 5.5 Hz, 1H), 2.73 – 2.56 (m, 4H), 2.43 (s, 3H),
2.31 (t, J = 7.6 Hz, 2H), 1.65 – 1.54 (m, 2H), 1.27 (d, J = 16.0 Hz, 24H), 0.88 (t, J = 7.0 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 174.23, 170.23, 169.91, 144.47, 136.20, 130.06,
127.60, 62.77, 62.73, 55.66, 55.32, 53.01, 34.79, 34.33, 32.07, 31.08, 29.84, 29.80, 29.77,
29.63, 29.51, 29.42, 29.29, 25.00, 22.84, 21.74, 14.28. MS (ESI) calculated for
C32H54N2O8S2, m/z 658.33, found 659.34 (M + H)+ and 676.37 (M + NH4+).
Synthesis of Compound 12: 2-(((2R)-2-((tert-butoxycarbonyl)amino)-3-((3-
hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl)thio)ethyl palmitate
—To a solution of compound 6d (180 mg, 0.29 mmol) in anhydrous CH2Cl2, were added
triethylamine (67 µL, 0.49 mmol) and di-tert-butyl dicarbonate (107 mg, 0.49 mmol). The
reaction mixture was stirred for 2 h and the solvent was then removed under vacuum. The
residue was purified using column chromatography (5% MeOH/ CH2Cl2) to obtain the
compound 12 (160 mg, 91%). 1H NMR (400 MHz, CDCl3) δ 7.27 (s, 1H), 5.47 (s, 1H), 4.66
(dt, J = 7.0, 3.3 Hz, 1H), 4.28 (ddd, J = 10.3, 8.8, 4.4 Hz, 3H), 3.99 (d, J = 3.1 Hz, 2H), 3.82
(s, 3H), 3.02 (ddd, J = 32.3, 13.9, 6.1 Hz, 2H), 2.84 (t, J = 6.6 Hz, 3H), 2.34 (t, J = 7.6 Hz,
2H), 1.62 (dd, J = 14.3, 7.0 Hz, 2H), 1.48 (s, 9H), 1.27 (s, 24H), 0.90 (t, J = 6.7 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 174.19, 170.83, 170.57, 155.69, 80.92, 63.09, 62.88,
55.21, 54.17, 52.96, 34.56, 34.36, 32.07, 31.31, 29.84, 29.80, 29.76, 29.62, 29.50, 29.41,
29.28, 28.40, 25.01, 22.84, 14.27. MS (ESI) calculated for C30H56N2O8S, m/z 604.38,
found 605.38 (M + H)+.
Synthesis of Compounds 14a: 2-(((R)-3-(((S)-3-acetoxy-1-methoxy-1-
oxopropan-2-yl)amino)-2-amino-3-oxopropyl)thio)ethyl palmitate—To a solution
of compound 12 (40 mg, 0.079 mmol) in pyridine (1 mL), was added acetic anhydride (15
µL, 0.158 mmol). The reaction mixture was stirred at room temperature for 1 h and the
solvent was removed to obtain the crude N-Boc intermediate 13a. The N-Boc group was
then removed by stirring compound 13a in 1 mL of trifluoroacetic acid for 15 min, followed
by removal of solvent by purging nitrogen. The residue was dried under vacuum to obtain
compound 14a in quantitative yield. 1H NMR (500 MHz, CDCl3) δ 8.18 (d, J = 7.7 Hz, 1H),
6.55 (s, 2H), 4.80 (dd, J = 7.5, 3.8 Hz, 1H), 4.41 (ddd, J = 27.2, 11.6, 3.9 Hz, 2H), 4.35 –
4.16 (m, 3H), 3.77 (s, 3H), 3.11 (ddd, J = 43.7, 14.6, 6.5 Hz, 2H), 2.82 (t, J = 6.6 Hz, 2H),
2.31 (t, J = 7.6 Hz, 2H), 2.03 (s, 3H), 1.66 – 1.53 (m, 2H), 1.35 – 1.09 (m, 24H), 0.87 (t, J =
7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.39, 171.23, 169.23, 63.19, 62.55, 53.13,
52.48, 52.39, 34.31, 33.04, 32.07, 30.89, 29.85, 29.83, 29.81, 29.79, 29.65, 29.51, 29.45,
29.31, 24.99, 22.84, 20.66, 14.27. MS (ESI) calculated for C27H50N2O7S, m/z 546.33,
found 547.34 (M + H)+.
Synthesis of Compound 14b: 2-(((R)-2-amino-3-(((S)-3-(butyryloxy)-1-
methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl)thio)ethyl palmitate—To a
solution of compound 12 (50 mg, 0.083 mmol) in anhydrous THF were added triethylamine
(36 µL, 0.25 mmol) and butyryl chloride (25 µL, 0.25 mmol). The reaction mixture was
stirred for 2 h and the solvent was then removed under vacuum. The residue was purified
using column chromatography (15% ethylacetate/hexanes) to obtain the N-Boc protected
intermediate 13b (25 mg, 45%). The N-Boc group was then removed by stirring compound
13b in 1 mL of trifluoroacetic acid for 15 min, followed by removal of the acid by purging
nitrogen. The residue was thoroughly dried under vacuum to obtain compound 14b in
quantitative yield. 1H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 7.6 Hz, 1H), 6.17 (s, 4H), 4.79
(dt, J = 7.6, 3.7 Hz, 1H), 4.49 (dd, J = 11.6, 4.1 Hz, 1H), 4.39 – 4.30 (m, 2H), 4.31 – 4.16
(m, 2H), 3.77 (s, 3H), 3.18 (dd, J = 14.7, 6.2 Hz, 1H), 3.05 (dd, J = 14.7, 7.1 Hz, 1H), 2.82
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(t, J = 6.5 Hz, 2H), 2.29 (dt, J = 19.0, 7.5 Hz, 4H), 1.60 (dd, J = 14.7, 7.4 Hz, 4H), 1.25 (s,
24H), 0.89 (dt, J = 14.0, 7.2 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 174.61, 173.77,
169.15, 167.87, 62.94, 62.39, 53.16, 52.64, 52.47, 35.77, 34.31, 32.80, 32.07, 30.71, 29.85,
29.82, 29.81, 29.78, 29.64, 29.51, 29.42, 29.29, 24.97, 22.84, 18.31, 14.27, 13.62. MS (ESI)
calculated for C29H54N2O7S, m/z 574.37, found 575.37 (M + H)+.
Compound 14c was synthesized similarly as compound 14b.
14c: 2-(((R)-2-amino-3-(((S)-1-methoxy-1-oxo-3-(palmitoyloxy)propan-2-
yl)amino)-3-oxopropyl)thio)ethyl palmitate—(44 mg, 63%). 1H NMR (400 MHz,
CDCl3) δ 7.87 (d, J = 7.6 Hz, 1H), 6.80 (s, 4H), 4.82 – 4.73 (m, 1H), 4.49 (dd, J = 11.6, 4.1
Hz, 1H), 4.42 – 4.17 (m, 4H), 3.77 (s, 3H), 3.21 (dd, J = 14.7, 5.8 Hz, 1H), 3.02 (dd, J =
14.7, 7.7 Hz, 1H), 2.81 (t, J = 6.5 Hz, 2H), 2.30 (dt, J = 19.4, 7.6 Hz, 4H), 1.68 – 1.50 (m,
4H), 1.25 (s, 46H), 0.88 (t, J = 6.8 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 174.85, 174.03,
169.05, 167.77, 62.88, 62.31, 53.20, 52.74, 52.48, 34.34, 33.91, 32.78, 32.08, 30.63, 29.86,
29.83, 29.82, 29.79, 29.65, 29.52, 29.42, 29.29, 29.21, 24.96, 24.85, 22.84, 14.27. MS (ESI)
calculated for C41H78N2O7S, m/z 742.55, found 743.56 (M + H)+.
Synthesis of Compound 16: 3-(((R)-2-acetamido-3-(((S)-3-hydroxy-1-
methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl)thio)propyl palmitate—To a
solution of compound 1517 (20 mg, 0.032 mmol) in anhydrous CH2Cl2 were added
triethylamine (5 µL, 0.038 mmol) and acetic anhydride (3 µL, 0.032 mmol). The reaction
mixture was stirred for 2 h. The solvent was removed under vacuum to obtain the residue
which was purified using column chromatography (6% MeOH/CH2Cl2), furnishing
compound 16 (10 mg, 59%). 1H NMR (500 MHz, DMSO) δ 8.41 (d, J = 7.6 Hz, 1H), 8.12
(d, J = 8.5 Hz, 1H), 5.07 (t, J = 5.6 Hz, 1H), 4.54 (td, J = 8.9, 4.9 Hz, 1H), 4.33 (dt, J = 7.7,
4.9 Hz, 1H), 4.10 – 4.03 (m, 2H), 3.70 (dt, J = 11.1, 5.6 Hz, 1H), 3.66 – 3.58 (m, 4H), 2.82
(dd, J = 13.7, 4.9 Hz, 1H), 2.57 (ddd, J = 9.2, 5.3, 3.0 Hz, 3H), 2.28 (td, J = 7.4, 2.8 Hz,
2H), 1.85 (s, 3H), 1.84 – 1.76 (m, 2H), 1.57 – 1.43 (m, 2H), 1.23 (s, 24H), 0.85 (t, J = 6.9
Hz, 3H). 13C NMR (126 MHz, DMSO) δ 172.96, 170.78, 170.75, 169.25, 62.41, 61.10,
54.75, 51.96, 51.88, 33.66, 33.44, 31.31, 29.06, 29.05, 29.02, 28.98, 28.89, 28.72, 28.69,
28.46, 28.15, 27.69, 24.45, 22.50, 22.12, 13.98. MS (ESI) calculated for C28H52N2O7S, m/z
560.35, found 561.35 (M + H)+.
TLR2-specific NF-κB induction: The induction of NF-κB in a TLR2-specific reporter gene
assay was quantified using HEK-Blue™ cells as previously described by us.23 HEK293
cells stably transfected with either human TLR2 or murine TLR2 and alkaline phosphatase
(sAP) were obtained from InvivoGen (San Diego, CA), and were maintained in HEK-
Blue™ Selection medium containing zeocin and normocin. Stable expression of secreted
alkaline phosphatase (sAP) under control of NF-κB promoters is inducible by TLR2
agonists, and extracellular sAP in the supernatant is proportional to NF-κB induction. HEK-
Blue cells were incubated at a density of ~105 cells/mL in a volume of 80 µL/well, in 384-
well, flat-bottomed, cell culture-treated microtiter plates until confluency was achieved, and
then stimulated with serially-diluted aliquots of compounds for 12 h. sAP was assayed
spectrophotometrically using an alkaline phosphatase-specific chromogen (present in the
HEK-detection medium as supplied by the vendor) at 620 nm. For antagonism assays, HEK-
Blue cells were incubated at a density of ~105 cells/mL in a volume of 80 µL/well and
stimulated with either PAM2CS (1 µg/mL) or lipoteichoic acid (1 µg/mL) in the presence of
graded concentrations of the test compounds as described for TLR7 previously.19,37
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EC50 Half-maximal effective concentration
EDCI 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
ESI-TOF Electrospray ionization-time of flight
HBTU O-benzotriazole-N,N,N’,N’-tetramethyl-uronium hexafluorophosphate
HEK Human embryonic kidney
HOBt 1-Hydroxybenzotriazole
IRAK-4 Interleukin-1 receptor-associated kinase 4
MPL monophosphoryl lipid A
MHC Major histocompatibility complex
NF-κB Nuclear factor-κB
PAM Palmitoyl
sAP Secreted alkaline phosphatase
SAR Structure activity relationship
TH1 Helper T lymphocyte, type 1
TH2 Helper T lymphocyte, type 2
THF Tetrahydrofuran
TLR Toll like receptor
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TLR2-specific NF-κB induction by selected analogues in human and murine TLR2 reporter
gene assays. Means and standard deviations of quadruplicate samples are shown.
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Syntheses of monoacyl lipopeptide 6d and its analogues.
Reagents and Conditions: i. (a) Boc2O, Et3N, H2O (b) H-Ser(tBu)-OMe.HCl, EDCI, HOBt,
Et3N, DMF; ii. Bu3P, CH2Cl2; iii. 2-Iodoethanol, Et3N, DMF; For compounds 5a–5g: iv.
RCOCl, Et3N, DMAP, CH2Cl2; For compounds 5h: v. RCOOH, HBTU, Et3N, DMAP,
DMF; vi. CF3COOH.
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Syntheses of analogues of 6d.
Reagents and Conditions: i. (a) 1-Bromotetradecane, Et3N, DMF (b) Boc2O, Et3N, CH2Cl2;
ii. LiOH, H2O, THF; iii. (a) 4, EDCI, DMAP, NMM, CH2Cl2 (b) CF3COOH
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Syntheses of N-alkyl, N-acyl and N-sulfonyl derivatives of 6d.
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Syntheses of O-acyl derivatives of 6d.
Reagents and conditions: i. (Boc)2O, Et3N, CH2Cl2; For compound 13a: ii. (CH3CO)2O,
pyridine; For compound 13b–13c: iii. RCl, Et3N, THF; iv. CF3COOH.
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Syntheses of N-acetyl derivative of homologue of 6d.
Reagents and conditions: i. (CH3CO)2O, Et3N, CH2Cl2.
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Table 1








6d 3.63 ± 0.125



























11d 1.01 ± 0.051
11e 1.64 ± 0.712
11f 3.80 ± 0.156
11g ND
11h 4.45 ± 0.325
11i ND
11j ND




















14a 2.97 ± 0.157
14b 5.47 ± 0.112
14c 5.95 ± 0.079
15 ND
16 5.52 ± 0.195
a
ND denotes no activity detected at 10 µM.
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